TEVA(MNTA): My central point is that the FDA may allow a non-substitutable generic, as discussed, despite the dubious appearance this may cause irt "public interest." There are just too many unknowns surrounding Teva's application, including whether it is still pending at all.
Market Data 
Markets 
AI
